SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Comment Letter for ASTROTECH (ASTC) — Mar 10, 2021

ASTROTECH Corp
Date: March 10, 2021 · CIK: 0001001907 · Accession: 0000000000-21-002878

AI Filing Summary & Sentiment

File numbers found in text: 333-253835

Date
March 10, 2021
Author
Not clearly detected
Form
UPLOAD
Company
ASTROTECH Corp

Letter

United States securities and exchange commission logo March 10, 2021 Eric Stober Chief Financial Officer Astrotech Corporation 2028 E. Ben White Blvd., Suite 240-9530 Austin, Texas 78741 Re:Astrotech Corporation Registration Statement on Form S-3 Filed March 3, 2021 File No. 333-253835 Dear Mr. Stober: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jordan Metoyer at 202-551-6001 or Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John R. Hempill, Esq.

Show Raw Text
United States securities and exchange commission logo
March 10, 2021
Eric Stober
Chief Financial Officer
Astrotech Corporation
2028 E. Ben White Blvd., Suite 240-9530
Austin, Texas 78741
Re:Astrotech Corporation
Registration Statement on Form S-3
Filed March 3, 2021
File No. 333-253835
Dear Mr. Stober:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jordan Metoyer at 202-551-6001 or Tim Buchmiller at 202-551-3635 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       John R. Hempill, Esq.